Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9041510 | 0.93 | SRD5A2 (0.47) | HTR2ACPB1KMT2AMGLLMEN1 | |
| SCHEMBL4674650 | 0.89 | MGLL (0.54) | KMT2AMGLLMEN1HSD11B1ALDH1A1 | |
| SCHEMBL7286908 | 0.89 | HTR2A (0.43) | HTR2ACPB1KMT2AMGLLMEN1 | |
| SCHEMBL18428493 | 0.85 | HTR2A (0.56) | HTR2ACPB1KMT2AMGLLMEN1 | |
| SCHEMBL324342 | 0.85 | HTR2A (0.56) | HTR2ACPB1KMT2AMGLLMEN1 | |
| SCHEMBL4675883 | 0.85 | ALDH1A1 (0.53) | MGLLALDH1A1SRD5A2 | |
| Bicarbonate SCHEMBL11468689 | 0.83 | HTR2A (0.54) | HTR2ACPB1KMT2AMGLLMEN1 | |
| SCHEMBL4672863 | 0.82 | KDM4E (0.53) | HTR2AKMT2AMGLLMEN1HSD11B1 | |
| SCHEMBL965420 | 0.81 | SRD5A2 (0.63) | HTR2ACPB1KMT2AMGLLMEN1 | |
| SCHEMBL3113279 | 0.81 | SRD5A2 (0.58) | HTR2ACPB1KMT2AMGLLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | claimed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | claimed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | claimed |
| EP-2405973-B1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2015-04-22 | — | — | EP | claimed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | claimed |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-03-27 | — | — | US | claimed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | claimed |
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | claimed |
| EP-2575969-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-04-10 | — | — | EP | claimed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| WO-2007045622-A1 | OXAZOLO [4 , 5-B] PYRIDINE COMPOUNDS AS NITRIC OXIDE SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2007-04-26 | — | — | WO | claimed |
| EP-0998451-B1 | SUBSTITUTED 3,3-DIAMINO-2-PROPENENITRILES, THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 2003-04-16 | — | — | EP | claimed |
| WO-2001056974-A2 | INHA INHIBITORS AND THEIR USE AS ANTIBACTERIALS | GENZYME CORPORATION (US) | 2001-08-09 | — | — | WO | claimed |
| EP-1019367-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | claimed |
| EP-0979227-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | claimed |
| WO-1999007672-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-02-18 | — | — | WO | claimed |
| WO-1998047882-A1 | 4,1-BENZOXAZEPINES, THEIR ANALOGUES, AND THEIR USE AS SOMATOSTATIN AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-29 | — | — | WO | claimed |
| EP-0126094-B1 | NEW 1,4-DIHYDROPYRIDINE ESTERS AND PREPARATION METHODS THEREOF AND DRUGS CONTAINING SAID ESTERS | CERMOL S.A. (CH) | 1990-06-20 | — | — | EP | claimed |
| US-4727066-A | CARDIOVASCULAR DISORDERS | CERMOL S.A. (CH) | 1988-02-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | HTR2A 2214/4885CPB1 1922/4885KMT2A 4258/4885 |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | CCNA1, CCND3, CCND1 | HTR2A 4184/4885CPB1 4249/4885KMT2A 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.